eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
1/2022
vol. 26
 
Share:
Share:
more
 
 
abstract:
Original paper

Prognostic significance of lymphocyte-to-monocyte ratio in patients with classical Hodgkin lymphoma before and after receiving first-line chemotherapy

Heba F. Taha
1
,
Lamiaa Mahmoud Kamel
2
,
Ahmed Embaby
3
,
Lobna A. Abdelaziz
4

1.
Department of Medical Oncology, Faculty of Medicine, Zagazig University, Zagazig, Egypt
2.
Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt
3.
Department of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt
4.
Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Contemp Oncol (Pozn) 2022; 26 (1): 69–77
Online publish date: 2022/03/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Despite the presence of a prognostic risk stratification sco-ring system for Hodgkin lymphoma (HL), the lymphocyte-to-monocyte ratio (LMR) is a simple and low-cost test that has been investigated as a prognostic marker to evaluate the clinical course and survival outcomes.

Material and methods
We prospectively enrolled 92 patients with classical HL (CHL), who were diagnosed and treated in the period from April 2017 to April 2020. Lymphocyte monocyte ratio cut-off values were estimated using receiver operating characteristic curves.

Results
We found that patients with LMR < 1.4 at the time of diagnosis had poorer progression-free survival (PFS) and overall survival (OS) than those with LMR > 1.4. Patients with increased LMR values after the first 2 cycles of chemotherapy had better PFS and OS; meanwhile, patients who had low LMR after the end of chemotherapy had poorer PFS and OS in comparison to patients who gained higher value after the completion of all cycles of chemotherapy.

Conclusions
A rise of LMR value indicated better outcome and better survival rate, so it can be an independent prognostic factor for survival and to predict outcome in patients with CHL.

keywords:

Hodgkin lymphoma, LMR, prognosis, chemotherapy

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.